MedPage Today -- Safety issues -- especially cardiovascular risks -- continue to dog rosiglitazone (Avandia) and echo in faint whispers that touch its classmate, pioglitazone (Actos). As a result, the question that emerged here at the American Diabetes Association meeting was all-encompassing -- should the thiazolidinedione class continue to be used at all?
